Analysis of hospital registry data found that people who were hospitalized due to bleeding in the brain and who had taken multiple antiplatelet medications, or medications stronger than aspirin, were ...

Antiplatelet monotherapy reduced bleeding, but dual therapy provided greater cardiovascular event protection in patients at ...

DUBLIN--(BUSINESS WIRE)--The "Antiplatelet Market: Analysis By Drug Class, By Route of Administration, By Distribution Channel, By Region Size and Trends" report has been added to ...

Potent antiplatelet therapy increased bleeding without signs of benefit regarding cardiovascular events in patients with ...

NANJING, China, June 26, 2026 /PRNewswire/ -- Recently, the NDA for Sumecigrel Capsule (formerly known as Vicagrel), a Class 1 innovative antiplatelet drug developed by Jiangsu Vcare PharmaTech ...

SHANGHAI, June 20, 2026 /PRNewswire/ -- CureGene Pharmaceutical today announced that the first participant has been successfully dosed in the U.S. pivotal clinical trial of Evategrel (CG-0255), its ...

CAMPBELL, Calif.--(BUSINESS WIRE)--Imperative Care, a medical technology company developing connected innovations to elevate care for people affected by stroke and other ischemic diseases, today ...

Current guidelines recommend dual antiplatelet therapy, a combination of aspirin and a P2Y 12 inhibitor, for 6–12 months after percutaneous coronary intervention with drug-eluting stent implantation ...